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Anatomic and dosimetric changes occur in head and neck cancer during 
fractionated proton radiotherapy, and the actual dose received by patient is 
considerably different from original plan. Adaptive radiotherapy aims to modify 
treatment according to changes that occur during proton therapy. Intensity 
modulated proton therapy for head and neck cancer (HNC) patients benefitted by 
adaptation to correct the dose perturbations caused by weight loss, tumor volume 
changes, setup and range uncertainties. The following sections have elaborated 
the rationale of adaptation in HNC, proton physics in HNC, studies comparing 
non-adaptive and adaptive intensity modulated proton therapy (IMPT) plans, 
reasons for adaptation and how to mitigate these changes.
Keywords: adaptative radiotherapy, proton, intensity modulated, head and neck 
cancer, anatomic changes, dosimetric changes, uncertainties
1. Introduction
Intensity Modulated Radiation Therapy (IMRT) with photons has become 
standard treatment for locally advanced head and neck cancer (HNC) because 
of its high conformality and better sparing of critical structures [1–3]. However 
proton therapy using spot scanning (Intensity Modulated Proton Therapy-IMPT) 
has shown superior dose distribution compared to IMRT in head and neck cancer 
patients [4–8]. The physical characteristics of proton i.e., its ability of sharp distal 
fall of inside tissue made substantial advantages over photon therapy. The unneces-
sary radiation to organ at risks (OARs) and nearby healthy tissues was significantly 
reduced with proton when compared with photons. The advantages of proton 
therapy (over photon) in head and neck malignancies have already documented in 
literature [9–10]. Protons significantly reduce the risk of xerostomia, dysgeusia, 
dysphagia, tube feeding dependence and hypothyroidism.
During radiation treatment of Head and neck cancer, changes in anatomy occur 
like shrinkage of tumor and normal tissues, which is in response to radiation and 
combined chemotherapy. So plan adaptation is desirable to optimally treat these 
patients undergoing anatomical modifications and weight loss. These little altera-
tions during proton therapy lead to huge dosimetric changes (like high dose to 
normal structures and low dose to target volume) because of sharp dose fall off 
between target volume (TV) and OAR, thus leading to increased complications and 
marginal failure. The influence of anatomical changes for proton therapy is more 
pronounced due to range uncertainties. To counteract these limitations, the best 
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possible strategy is Adaptive Radiotherapy (ART) of proton, i.e., repeat imaging 
and repeat planning to adapt to actual patient anatomy.
2. Physics: HNC
The anatomy of head and neck is complex and tumor is surrounded by many 
critical structures or organ at risk (OAR) like parotid, spinal cord, constrictors, 
thyroid etc.
The physical properties of protons are very useful for the treatment of these 
cancers. The physical properties of photon Vs proton are depicted in Table 1. 
Protons travel a well-defined distance, losing energy at an increasing rate before 
stopping, forming the characteristic Bragg peak. The distal penumbra is limited 
and is well adapted to the treatment of head and neck cancer. Besides this, a thera-
peutic beam can be produced by (a) Passive Scattering Proton Therapy (PSPT), 
i.e., where narrow monoenergetic beam pass through a range modulation wheel 
and scattering it laterally to cover the tumor volume, (b) Pencil Beam Scanning 
(PBS), i.e., scanning the narrow (pencil) beams magnetically by energy layers. To 
create homogenous depth dose, the Spread Out Bragg Peak (SOBP) is created by 
summing of all pristine Bragg peaks.
Passive Scattering PT is not well adapted to the complex anatomies of head and 
neck cancer compared to pencil beam scanning. In PSPT, the dose distribution 
is conformed laterally with an aperture, and range uncertainties are minimized 
through range compensator smearing. In large volume tumors, field junctions are 
used, known as beam patching. While beam patching is sensitive to set-up uncer-
tainties. However, in Pencil Beam Scanning (PBS), the beam is scanned magneti-
cally which facilitates intensity modulation and allowing to treat tumor surrounded 
by complex anatomies.
In PBS, there are two different optimization techniques:
i. Single-field optimization (SFO) and
ii. Multi-field optimization (MFO/IMPT).
In the SFO approach, each beam is optimized independently to achieve a uni-
form dose to the target. SFO is quite robust to changes. With IMPT, the optimization 
Variable Photon Proton
At beam entrance i. Maximum dose in beam path i. No maximum dose, Flat 
entrance dose
ii. Skin sparing effect present (build up dose 
after certain depth)
ii. No skin sparing effect
Around target No distal fall off Distal fall off seen (proton stop)
After target Exit dose seen No exit dose (no dose behind 
target)
Laterally Lateral penumbra is stable relative to depth Lateral penumbra increase with 
depth
Everywhere Electron contamination Neutron contamination
Table 1. 
Physics: photon vs proton.
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process simultaneously optimizes the intensities of the spots from all of the beams, 
thereby irradiating the tumor heterogeneously with each beam but providing a 
uniform dose to it. IMPT is therefore more relevant for the complex head and neck 
anatomy and OAR constraints. IMPT is clearly less robust than SFO in the presence 
of uncertainties.
The advantage in IMPT, we can use multiple field arrangements for better cur-
vilinear dose distributions around critical structures and this is less easily achieved 
with single field optimization. The critical structures are better spared in MFO/
IMPT than SFO. The MFO plan can be made more robust by taking into account 
setup and range uncertainties during optimization.
3. Dosimetric studies
In photons, adaptive planning is done mainly because of change in size of tumor 
and relative shift in critical structures. While in protons, the sharp dose fall off 
and air-borne interface (different stopping power) makes proton very sensitive to 
variations in treatment depths. Proton therapy is more susceptible to tissue density 
heterogeneities as proton range is density dependent. In the proton beam path if 
bone is present the beam is pulled back, while beam is pushed forward if air is in the 
path.
Multiple studies have shown that proton therapy in head and neck malignancies 
produce similar or better target coverage and conformity than IMRT. Minor varia-
tions in change in anatomy would result in significant change in dose distribution 
in proton therapy. Very few studies have quantified the degree of dose variations 
during treatment for patients undergoing IMPT. The three studies are summarized 
in Table 2.
Parameter Simone et al., 2011 [11] J Gora et al., 2015 [12] Wu et al., 2017 [13]
Number n = 10 n = 6 n = 10





70 70, 63, 56 70
Timing of 
replanning








BS (Dmax, Gy) 31.3 29 24.7 21.1 10.15 9.8
SC (Dmax, Gy) 30.5 28.4 25.3 20.8 10.95 10.58
I/L parotid 
(Dmean, Gy)












35.3 31 39.4 45.9 — —
IMPT-intensity modulated proton therapy, BS-brain stem, SC-spinal cord, I/L-ipsilateral, C/L-contralateral.
Table 2. 
Studies showing dosimetric results and comparison between non-adaptive and adaptive IMPT plans.
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4. Reasons for adaptation
i. Target deformation:
In patients of head and neck cancer treated with photons, various studies shown 
that the reduction in target volume ranges from 5 to 13% during treatment [14–16]. 
In Gunn et al. [17], out of 50 patients of oropharyngeal cancers treated with IMPT, 
in view of weight loss and tumor volume changes 19 patients (38%) had adaptive 
replanning.
ii. Anatomical and OAR deformation
The potential anatomical changes are weight loss, decrease in size of surgical 
flap, reduction in swelling, parotid gland shrinkage etc. [16, 18, 19]. Figure 1 depicts 
the reasons of replanning.
Figure 1. 
Reasons for adaptation: (A) anatomical change – weight loss, (B) target deformation – nodal response, and  
(C) beam path change.
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iii. Beam path change
As proton range is density dependent, it is more susceptible than photons. 
The nasal cavity and paranasal sinuses region contains variable amount of 
complicated structures such as bone, mucosa, tumor tissue, collected fluid, and 
air, which can alter the different proton beam ranges. Variations in air and fluid 
content in the nasal cavity and paranasal sinuses during the course of radio-
therapy could affect the proton dose distribution. Clearing or opacification of 
sinuses may result in shift of the high dose deposition, potentially lead to change 
in dose to the targets and critical structures (Figure 2). Late toxicities such as 
brain injury, cerebrospinal fluid leakage, and vision loss have been reported 
for patients with head and neck cancer patients treated with proton or carbon 
therapy [20–22].
In a study by Fukumitsu et al., twenty patients of nasal and paranasal sinuses 
received proton therapy and in 18 out of 20 cases, the air content in the cavi-
ties increased. This resulted an increase in dose to brainstem above 60Gy in 3 
patients and increase in dose above 50Gy in 10 patients [23]. Susharina et al. 
also demonstrated that change in aeration in vicinity of target lead to decreased 
dose to target (5%) and increased dose to optic structures and brain  
stem [24].
iv. Uncertainties
The main factors leading to range uncertainty are
a. Range calculation in TPS
i. Inaccuracies arising from CT (HU to stopping power conversion, CT recon-
struction, HU uncertainty like metal artifacts, partial volume effect)
ii. Inaccuracies arising from dose algorithm
b. Discrepancies between planned and delivered dose – like geometric changes 
(setup and motion) and density heterogeneities.
Figure 2. 




The process of adaptive radiotherapy identified by weight loss, mask fitting, 
changes in patient setup, regularly planned intervals, treatment response assessed 
by CBCT scans, diagnostic CT or MRI scans (tumor shrinkage), recalculating the 
dose delivered to targets and OARs.
The other approaches are planning QACT (quality assurance CT) at regular 
intervals (after every 10 fractions) as reduction in parotid and target volumes occur 
in early third week resulting in huge dosimetric differences. In the modern proton 
therapy, image guidance with daily CBCT helps in identifying the anatomical 
changes and early treatment response.
The IMPT treatment uncertainties can be mitigated by robust optimization. The 
robust optimization technique is a robust plan generated using CTV as primary 
target and not requiring geometrically expanded PTV. The robust optimization 
method takes into account setup and range uncertainty directly during spot 
weighting. Therefore it does not need extra volume to be irradiated.
There is no consensus on most appropriate timing regimen for adaptation/
replanning during proton therapy.
6. Conclusion
Proton therapy in head and neck cancer is associated with tissue and target 
volume changes leading to higher doses to normal tissues (salivary glands/DARS). 
Adaptation once or twice in middle of treatment will reduce unnecessary doses 
to parotid, swallowing structures etc., thus improving patient’s quality of life by 
reducing the risk of xerostomia and tube feeding dependence.
Acknowledgements
I would like to express my sincere gratitude to my teachers and colleagues for 
their guidance and support. I especially thank my wife for her continuous support 






CBCT cone beam computed tomography
CT computed tomography
C/L parotid-contralateral parotid
DARS dysphagia/aspiration at risk structures
HU Hounsfield Unit
HNC head and neck cancer
I/L parotid-ipsilateral parotid
IMRT intensity modulated radiation therapy
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IMPT intensity modulated proton therapy
MFO multi field optimization
MRI magnetic resonance imaging
OARs organ at risk
PBS pencil beam scanning
PSPT passive scanning proton therapy
SFO single field optimization
SC spinal cord
TV target volume
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